Pluristem Therapeutics, Inc.
PSTI
|
$1.0
-2.91%
8.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (192.0% volume)
Earnings Calendar: 2022-09-12
Market Cap: $ 32,347,584
http://www.pluristem.com
Sec Filling | Patents | 146 employees
(IL) Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
israel t-cell clinical trials treatment ceiling
add to watch list Paper trade email alert is off
Press-releases
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
Published: 2023-03-13 (Crawled : 17:00) - globenewswire.com
PLUR | $5.22 3.37% 3.26% 24K
|
Manufacturing
|
| O: -5.56%
H: 9.41%
C: 3.52%
award
Pluri to Present and Participate in Upcoming Conferences
Published: 2022-10-31 (Crawled : 16:00) - biospace.com/
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
| Email alert
Add to watchlist
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
Published: 2022-09-29 (Crawled : 12:00) - biospace.com/
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
| Email alert
Add to watchlist
ceo financial
Global Stem Cells Market Report 2022: Ongoing Developments in Regenerative Medicine Presents Avenues for Future Growth
Published: 2022-09-27 (Crawled : 11:00) - prnewswire.com
BRTX | $1.39 -3.47% -3.6% 160K
|
Professional, Scientific, and T...
|
| O: -1.18%
H: 5.16%
C: -2.38%
SNNUF | $11.93 -1.12% 710
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
NUVA | $39.75 -2.24% -2.29% 0
|
Health Technology
|
| O: 1.11%
H: 1.05%
C: -1.23%
ATHX | $0.1018 -40.86% 95M
|
Health Technology
|
| O: 0.7%
H: 21.68%
C: -0.7%
ongoing global report growth market
€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
| Email alert
Add to watchlist
treatment osteoarthritis granted study
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
Published: 2022-07-25 (Crawled : 06:00) - globenewswire.com
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
|
| O: -2.85%
H: 2.94%
C: -1.96%
technology therapeutics platform
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
Published: 2022-07-13 (Crawled : 11:00) - biospace.com/
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
|
| O: -12.2%
H: 2.78%
C: -1.85%
topline results study
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
Published: 2022-03-23 (Crawled : 12:00) - biospace.com/
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
|
| O: -1.97%
H: 8.04%
C: 4.02%
blood
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
Published: 2022-03-08 (Crawled : 12:30) - globenewswire.com
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
|
| O: -8.87%
H: 8.11%
C: 2.7%
food
Pluristem CEO Issues Shareholder Update
Published: 2022-03-02 (Crawled : 13:30) - globenewswire.com
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
|
| O: -7.1%
H: 8.24%
C: 7.06%
ceo
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10